1-13 of 13
Michael V. Seiden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA

Xiaoji Chen, Zhao Dong, Earl Hubbell, Kathryn N. Kurtzman, Geoffrey R. Oxnard, Oliver Venn, Collin Melton, Christina A. Clarke, Rita Shaknovich, Ting Ma, Gerry Meixiong, Michael V. Seiden, Eric A. Klein, Eric T. Fung, Minetta C. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4221–4229.
https://doi.org/10.1158/1078-0432.CCR-21-0417
Published: 01 August 2021
View articletitled, Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Open the PDF for Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA in another window
Includes: Supplementary data
Journal Articles

Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma

Jean-Pierre Gillet, Anna Maria Calcagno, Sudhir Varma, Ben Davidson, Mari Bunkholt Elstrand, Ram Ganapathi, Aparna A. Kamat, Anil K. Sood, Suresh V. Ambudkar, Michael V. Seiden, Bo R. Rueda, Michael M. Gottesman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (11): 3197–3206.
https://doi.org/10.1158/1078-0432.CCR-12-0056
Published: 31 May 2012
View articletitled, Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma
Open the PDF for Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma in another window
Includes: Supplementary data
Journal Articles

Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles

Harikrishna Devalapally, Zhenfeng Duan, Michael V. Seiden, Mansoor M. Amiji
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (10): 3193–3203.
https://doi.org/10.1158/1078-0432.CCR-07-4973
Published: 15 May 2008
View articletitled, Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles
Open the PDF for Modulation of Drug Resistance in Ovarian Adenocarcinoma by Enhancing Intracellular Ceramide Using Tamoxifen-Loaded Biodegradable Polymeric Nanoparticles in another window
Journal Articles

Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors

Anna Berkenblit, Joseph P. Eder, Jr., David P. Ryan, Michael V. Seiden, Noriaki Tatsuta, Matthew L. Sherman, Thomas A. Dahl, Bruce J. Dezube, Jeffrey G. Supko
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 584–590.
https://doi.org/10.1158/1078-0432.CCR-06-0964
Published: 25 January 2007
View articletitled, Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors
Open the PDF for Phase I Clinical Trial of STA-4783 in Combination with Paclitaxel in Patients with Refractory Solid Tumors in another window
Journal Articles

SD-1029 Inhibits Signal Transducer and Activator of Transcription 3 Nuclear Translocation

Zhenfeng Duan, James E. Bradner, Edward Greenberg, Ross Levine, Rosemary Foster, Jennifer Mahoney, Michael V. Seiden
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (22): 6844–6852.
https://doi.org/10.1158/1078-0432.CCR-06-1330
Published: 22 November 2006
View articletitled, SD-1029 Inhibits Signal Transducer and Activator of Transcription 3 Nuclear Translocation
Open the PDF for SD-1029 Inhibits Signal Transducer and Activator of Transcription 3 Nuclear Translocation in another window
Journal Articles

Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer

Zhenfeng Duan, Rosemary Foster, Debra A. Bell, Jennifer Mahoney, Kathryn Wolak, Ami Vaidya, Constanze Hampel, Hang Lee, Michael V. Seiden
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5055–5063.
https://doi.org/10.1158/1078-0432.CCR-06-0861
Published: 01 September 2006
View articletitled, Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer
Open the PDF for Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer in another window
Journal Articles

Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors

David P. Ryan, Joseph P. Eder, Jr., Thomas Puchlaski, Michael V. Seiden, Thomas J. Lynch, Charles S. Fuchs, Philip C. Amrein, Darrell Sonnichsen, Jeffrey G. Supko, Jeffrey W. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2222–2230.
https://doi.org/10.1158/1078-0432.CCR-0980-3
Published: 08 April 2004
View articletitled, Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors
Open the PDF for Phase I Clinical Trial of the Farnesyltransferase Inhibitor BMS-214662 Given as a 1-Hour Intravenous Infusion in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors

Jeffrey G. Supko, Joseph P. Eder, Jr., David P. Ryan, Michael V. Seiden, Thomas J. Lynch, Phillip C. Amrein, Donald W. Kufe, Jeffrey W. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5178–5186.
Published: 12 November 2003
View articletitled, Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors
Open the PDF for Phase I Clinical Trial and Pharmacokinetic Study of the Spicamycin Analog KRN5500 Administered as a 1-Hour Intravenous Infusion for Five Consecutive Days to Patients with Refractory Solid Tumors in another window
Journal Articles

Overexpression of MAGE/GAGE Genes in Paclitaxel/Doxorubicin-resistant Human Cancer Cell Lines

Zhenfeng Duan, Yifei Duan, Diana E. Lamendola, Rushdia Z. Yusuf, Rizwan Naeem, Richard T. Penson, Michael V. Seiden
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2778–2785.
Published: 01 July 2003
View articletitled, Overexpression of MAGE/GAGE Genes in Paclitaxel/Doxorubicin-resistant Human Cancer Cell Lines
Open the PDF for Overexpression of MAGE/GAGE Genes in Paclitaxel/Doxorubicin-resistant Human Cancer Cell Lines in another window
Journal Articles

A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors

Michael V. Seiden, Shu-Wing Ng, Jeffrey G. Supko, David P. Ryan, Jeffrey W. Clark, Thomas Lynch, Kuan-Chun Huang, David Kwiatkowski, Arthur Skarin, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 691–697.
Published: 01 March 2002
View articletitled, A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors
Open the PDF for A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies

David P. Ryan, Jeffrey G. Supko, J. Paul Eder, Michael V. Seiden, George Demetri, Thomas J. Lynch, Alan J. Fischman, John Davis, Jose Jimeno, Jeffrey W. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (2): 231–242.
Published: 01 February 2001
View articletitled, Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of Ecteinascidin 743 Administered as a 72-Hour Continuous Intravenous Infusion in Patients with Solid Malignancies in another window
Journal Articles

Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype

Zhenfeng Duan, Aynn J. Feller, Richard T. Penson, Bruce. A. Chabner, Michael V. Seiden
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (11): 3445–3453.
Published: 01 November 1999
View articletitled, Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype
Open the PDF for Discovery of Differentially Expressed Genes Associated with Paclitaxel Resistance Using cDNA Array Technology: Analysis of Interleukin (IL) 6, IL-8, and Monocyte Chemotactic Protein 1 in the Paclitaxel-resistant Phenotype in another window
Journal Articles

A Phase I Study of Continuous Infusion Doxorubicin and Paclitaxel Chemotherapy with Granulocyte Colony-Stimulating Factor for Relapsed Epithelial Ovarian Cancer

Linda R. Duska, Richard Penson, Jeffrey G. Supko, Dianne M. Finkelstein, Thomas Makastorsis, Joan Gallagher, Karen Borden, Annekathryn Goodman, Arlan F. Fuller, Najmosama Nikrui, Michael V. Seiden
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (6): 1299–1305.
Published: 01 June 1999
View articletitled, A Phase I Study of Continuous Infusion Doxorubicin and Paclitaxel Chemotherapy with Granulocyte Colony-Stimulating Factor for Relapsed Epithelial Ovarian Cancer
Open the PDF for A Phase I Study of Continuous Infusion Doxorubicin and Paclitaxel Chemotherapy with Granulocyte Colony-Stimulating Factor for Relapsed Epithelial Ovarian Cancer in another window